Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Why Modern Pharma Requires A Central Nervous System For Assets
Ed Garibian, LLumin CEO and software entrepreneur, has 35 years of experience in machine maintenance, asset management & IoT technologies. Within manufacturing environments, equipment breakdown is an expensive inconvenience. In pharma, it is a…
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
Company announcement No. 28 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 26, 2026) Copenhagen, Denmark, June 29, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…
One Nation's new MP owns five properties, pharma stocks
One Nation's newly elected federal MP David Farley has disclosed a raft of financial interests, including stakes in obscure ASX-listed stocks, trading accounts and an expansive property portfolio. Under current lower house guidelines, all MPs must…
Rockefeller Capital Management L.P. Purchases 81,747 Shares of Royalty Pharma PLC $RPRX
Rockefeller Capital Management L.P. increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 1,347.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The…
Stock Market Opening Bell: Sensex Falls 0.06%, Nifty 50 Surges 0.02% - Here's Why
Stock Market Opening Bell: The Indian benchmark stock market indices opened, following a mixed trend in global markets post fresh escalations in US-Iran war over the weekend. While Nifty 50 opened 0.02% higher at 77055.21 level, Sensex fell as much…
Israeli health-tech conference opens in Jerusalem with 1,800 participants
The Israel Advanced Technology Industries (IATI) opened MIXiii Health-Tech.IL 2026 in Jerusalem on Monday, bringing roughly 1,800 participants and representatives from more than 40 countries to the International Convention Center, organizers said.
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO)
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby's commercial launch and a robust late-stage pipeline targeting rare genetic diseases. BBIO's $14bn+ valuation is underpinned by four potential blockbuster drugs by 2030, with key NDA catalysts…
Micron And The Price Of Certainty (NASDAQ:MU)
Micron Technology, Inc. shifts to a partially contracted business model, with SCAs covering over half of future revenue and improving visibility. SCAs provide downside protection via floor prices but limit upside with ceilings, complicating…
Nifty prediction today - June 29, 2026: Nifty futures may witness a brief blip before rally
Nifty 50 began today's session flat at 24,062 versus last week's close of 24,056. It is now trading at 24,060. The advance/decline ratio of Nifty 50 currently stands at 29/21, showing a bullish bias. Dr Reddy's Laboratories, up nearly 4 per cent…
PBM lobby goes on the offensive
The nation's top pharmacy benefit manager (PBM) lobbying group is going on the offensive, stepping up its advocacy efforts against the pharmaceutical industry after Congress passed a PBM industry overhaul last winter. The pharmaceutical industry…
Danaher: Why I'm Not Paying 24x P/E For 8% EPS Growth (NYSE:DHR)
Danaher (DHR) is a high-quality life sciences holding company, but current valuation does not justify a buy. DHR's reliance on M&A and exposure to pharma spending cycles pose risks, with organic growth slowing to just above 4% AEPS in 2025. Despite…
Sensex drops over 300 points, Nifty slips as geopolitical tensions weigh on markets
Equity benchmarks traded lower in Monday's mid-session after a flat opening following a long weekend, as renewed geopolitical tensions weighed on investor sentiment. Domestic markets remained cautious after fresh military exchanges between the US…
George Medicines appoints Brendan Walsh as Senior Vice President of Supply Chain & Technical Operations
Brendan Walsh brings more than 20 years of operational leadership to support George Medicines' global commercial expansion of GMRx2 London, UK, Boston, MA, 29 June 2026 – George Medicines, a late-stage biopharmaceutical company focused on…
Editorial and Content Jobs Hiring Now Across Film, Tech, and Government
For years, the industry talked about generalists. Every job description wanted someone who could write, edit, shoot video, manage social, and build a content calendar before lunch. That pendulum is swinging back. Today's most compelling job…
3 No-Brainer Dividend Stocks to Buy Right Now
With the S&P 500 looking historically expensive at 31 times earnings, it's a good time to buy a few defensive dividend stocks to hedge against a market crash. These stocks might also swoon during a downturn, but they'll reward patient investors…
Receive a Daily briefing on Pharma Industry News
Get Started